Vector Biopharma AG

Four axes of risk map how companies founded in the last five years are innovating in CAR T and TCR T cells

A snapshot of gene therapy and CAR T innovation, the emergence of protein stabilization, and new thinking in neurology

After creating microbes that can degrade molecules in the gut, the Tencent-backed company is moving on microbes that can produce biologics in vivo

Capstan debuts with a Pfizer Ventures-led $102M series A, Penn technology to create in vivo cell therapies

Companies delivering DNA- and RNA-encoded CARs aim to sidestep the challenges of ex vivo reprogramming

Versant start-up using $30M series A to advance its gene delivery platform based on tech from Andreas Plückthun’s University of Zurich lab